- Home
- EPIX vs ASRT Comparison
EPIX vs ASRT Comparison
Compare EPIX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- ASRT
- Stock Information
- Founded
- EPIX 2009
- ASRT 1995
- Country
- EPIX Canada
- ASRT United States
- Employees
- EPIX N/A
- ASRT N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- ASRT Health Care
- Exchange
- EPIX Nasdaq
- ASRT Nasdaq
- Market Cap
- EPIX 65.3M
- ASRT 65.7M
- IPO Year
- EPIX N/A
- ASRT 1997
- Fundamental
- Price
- EPIX $1.77
- ASRT $0.62
- Analyst Decision
- EPIX Hold
- ASRT Strong Buy
- Analyst Count
- EPIX 3
- ASRT 3
- Target Price
- EPIX $2.00
- ASRT $3.08
- AVG Volume (30 Days)
- EPIX 235.8K
- ASRT 420.6K
- Earning Date
- EPIX 05-13-2025
- ASRT 05-05-2025
- Dividend Yield
- EPIX N/A
- ASRT N/A
- EPS Growth
- EPIX N/A
- ASRT N/A
- EPS
- EPIX N/A
- ASRT N/A
- Revenue
- EPIX N/A
- ASRT $124,961,000.00
- Revenue This Year
- EPIX N/A
- ASRT N/A
- Revenue Next Year
- EPIX N/A
- ASRT $11.20
- P/E Ratio
- EPIX N/A
- ASRT N/A
- Revenue Growth
- EPIX N/A
- ASRT N/A
- 52 Week Low
- EPIX $1.40
- ASRT $0.51
- 52 Week High
- EPIX $7.88
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- EPIX 62.93
- ASRT 43.68
- Support Level
- EPIX $1.42
- ASRT $0.57
- Resistance Level
- EPIX $1.91
- ASRT $0.80
- Average True Range (ATR)
- EPIX 0.09
- ASRT 0.05
- MACD
- EPIX 0.03
- ASRT 0.01
- Stochastic Oscillator
- EPIX 72.16
- ASRT 77.14
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.